Jonathon McCrary, PA
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $944 and has fallen 67.2% since, to $309 in 2025.
Across 93 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$226
- Atricure, Inc.$200
- Novo Nordisk$177
- AstraZeneca$158
- Alnylam Pharmaceuticals Inc.$152
- Amgen$137
- plus $764 from 20 others
What the payments were for
- Food & beverage$1,814100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 17 | $226 |
| Atricure, Inc. | 2 | $200 |
| Novo Nordisk | 10 | $177 |
| AstraZeneca | 7 | $158 |
| Alnylam Pharmaceuticals Inc. | 9 | $152 |
| Amgen | 9 | $137 |
| Abbott | 2 | $108 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $89 |
| Daiichi Sankyo Inc. | 3 | $73 |
| Boston Scientific | 3 | $72 |
| Boehringer Ingelheim | 4 | $62 |
| Bayer | 3 | $53 |
| Medtronic | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Lilly USA, LLC | 2 | $32 |
| Lexicon Pharmaceuticals, Inc. | 2 | $29 |
| Cvrx, Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $20 |
| Cardiac Dimensions, Inc. | 1 | $19 |
| Silk Road Medical, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Medexus Pharma, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Impulse Dynamics (USA) Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,814 in reported general payments places this provider in the 75th percentile of 94 surgical providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 11 | $7,584 |
| ClopidogrelClopidogrel Bisulfate | 11 | $195 |
Paid to pharmacies, not to this prescriber.
Other surgical in Tulsa
- Anne EdmondsTulsa$15K
- Isaac EdmondsTulsa$7K
- Camryn CorwinTulsa$5K
- Bryce WrightTulsa$4K
- Jamie TeeterTulsa$3K
- Shawna LiszewskiTulsa$3K
- Laura JuarezTulsa$3K
- Kristi KrebsTulsa$2K
- Crista HobbsTulsa$2K
- Jarret KellerTulsa$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.